Insud Pharma secures “Excellent” rating in the Profarma programme

Madrid, 10 July 2023

  • It is a recognition of the brands of the group Chemo, Exeltis and mAbxience for their commitment to industrial development and investment in our country
  • It is the third consecutive year that the group has received this rating from the Ministry of Industry

The Spanish pharmaceutical group Insud Pharma and its brands Chemo, Exeltis and mAbxience have obtained, for the third consecutive year, the qualification "EXCELLENT" in the Profarma 2022 Plan, in recognition of its industrial activity and its commitment to development and innovation in our country.

This plan, an initiative of the Ministry of Industry, Energy and Tourism, grants the highest mark to the Spanish multinational, with headquarters in Madrid and a presence in forty countries, as a result of its commitment to the development of the industrial structure in Spain and its investment effort both in production, as in R&D.
Profarma aims to increase the competitiveness of the pharmaceutical industry in Spain and, to this end, each year qualifies the participating companies based on their excellence in different industrial, economic and research aspects.


Press contact

Communication Department
Edificio Ebrosa - Manuel Pombo Angulo, 28 3rd floor
28050 Madrid, Spain.

Tel: +34 91 771 15 00